You are here

ARCHER PHARMACEUTICALS, INC.

Company Information
Address
2040 WHITFIELD AVE
SARASOTA, FL 34243-3922
United States



Information

UEI: F8JZB7RBLFR6

# of Employees: 0


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    Amount: $1,511,397.00

    Pathological hallmarks of Alzheimerandapos;s disease (AD) include extracellular deposits of Aβ peptides, intraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammation. Most ...

    STTRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    Amount: $224,920.00

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Pre-clinical Development of a Therapeutic for Alzheimer's Disease

    Amount: $150,000.00

    DESCRIPTION (provided by applicant): The A2 peptide is widely thought to be implicated in the pathogenesis of Alzheimer's Disease (AD) and A2-lowering strategies are being pursued by most maj ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government